Pharmacokinetics of a new galenical formulation of oral cyclosporine a in stable kidney transplanted patients
Foradori, A.C.; Martínez, L.; Vacarezza, A.; Elberg, L.; Loveluck, A.; Pinto, C.
Transplantation Proceedings 26(5): 2969-2972
1994
ISSN/ISBN: 0041-1345 PMID: 7940937 Document Number: 432793
Document emailed within 1 workday
Related Documents
Capone, D.; Stanziale, P.; Balletta, M.M.; Imperatore, P.; De Marino, V.; Pisanti, N. 1992: Evaluation of monoclonal/polyclonal ratio in kidney-transplanted patients treated with cyclosporine International Journal of Clinical Pharmacology Research 12(3): 123-128Soni, S.D.; Tench, D.; Ashwood, T.J.; Movin, G. 1990: Pharmacokinetics of an oral controlled release formulation of remoxipride: a double-blind, crossover comparison with conventional formulation in chronic schizophrenics Acta Psychiatrica Scandinavica. Supplementum 358: 45-47
Winkler, M.; Haller, G.; Oldhafer, K.; Bechstein, W.O.; Kattner, A.; Maibücher, A.; Färber, L.; Ringe, B.; Christians, U.; Neuhaus, P.; Pichlmayr, R. 1996: A new oral formulation of cyclosporine for early oral immunosuppressive therapy in liver transplant recipients Transplantation 62(8): 1063-1068
Laine, J.; Hoppu, K.; Jalanko, H.; Rönnholm, K.; Holmberg, C. 1997: Kidney function after 1:1 conversion to the cyclosporine microemulsion formulation in children with liver allografts Transplantation 63(12): 1768-1772
Stüttgen, G.; Bauer, E. 1988: Penetration and permeation into human skin of fusidic acid in different galenical formulation Arzneimittel-Forschung 38(5): 730-735
Kovarik, J.M.; Mueller, E.A.; Johnston, A.; Hitzenberger, G.; Kutz, K. 1993: Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation PharmacoTherapy 13(6): 613-617
Holt, D.W.; Mueller, E.A.; Kovarik, J.M.; van Bree, J.B.; Richard, F.; Kutz, K. 1995: Sandimmun neoral pharmacokinetics: impact of the new oral formulation Transplantation Proceedings 27(1): 1434-1437
Venkataramanan, R.; Jain, A.; Warty, V.W.; Abu-Elmagd, K.; Furakawa, H.; Imventarza, O.; Fung, J.; Todo, S.; Starzl, T.E. 1991: Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine Transplantation Proceedings 23(1 Part 2): 931-933
Kuhnz, W.; al-Yacoub, G.; Fuhrmeister, A. 1992: Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation Contraception 46(5): 455-469
Cainazzo, M.M.; Pinetti, D.; Savino, G.; Bartiromo, M.; Forgione, A.; Bertolini, A. 2005: Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers Drugs under Experimental and Clinical Research 31(3): 115-121
Diliz, H.S.; Olivera, M.A.; Kershenobich, D.; Mercado, M.A.; Orozco, H. 1996: Change of conventional cyclosporine to neoral cyclosporine formulation in long-term liver transplant recipients Transplantation Proceedings 28(6): 3348-3350
Degen, J.; Wölke, E.; Seiberling, M.; Thomann, P.; Völter-Erhardt, H. 1997: Comparison of the relative bioavailability and pharmacokinetics of estrone after oral administration of esterified estrogens in a tablet formulation and an aqueous suspension Arzneimittel-Forschung 47(2): 208-212
Busnach, G.; Stragliotto, E.; Minetti, E.; Perego, A.; Brando, B.; Broggi, M.L.; Civati, G. 1998: Effect of n-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients: a randomized placebo-controlled study Journal of Nephrology 11(2): 87-93
Stuart, G.S.; Moses, A.; Corbett, A.; Phiri, G.; Kumwenda, W.; Mkandawire, N.; Chintedze, J.; Malunga, G.; Hosseinipour, M.; Cohen, M.S.; Stanczyk, F.Z.; Kashuba, A.D.M. 2011: Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi Journal of Acquired Immune Deficiency Syndromes 58(2): E40-E43
Svehag, S.E.; Olander, R.; Sundqvist, K.G. 1973: Occurrence and cross-reactivity of heterophile antibodies and anti-kidney antibodies in kidney transplanted patients and patients with renal disease Clinical and Experimental Immunology 13(2): 191-202
Neumayer, H.H.; Budde, K.; Färber, L.; Haller, P.; Kohnen, R.; Maibücher, A.; Schuster, A.; Vollmar, J.; Waiser, J.; Luft, F.C. 1996: Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year Clinical Nephrology 45(5): 326-331
Lindberg, A.; Odlind, B.; Tufveson, G.; Lindström, B.; Gabrielsson, J. 1986: The pharmacokinetics of cyclosporine a in uremic patients Transplantation Proceedings 18(6 Suppl 5: 144-152
Vens-Cappell, B.; Hilgenstock, C.; Gellert, M.; Kühle, K.; Reifferscheid, I.; Winckler, P.; Bührens, K.G. 1993: Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration Arzneimittel-Forschung 43(3): 346-350
Cheymol, G. 1993: Pharmacokinetics and therapeutic monitoring of cyclosporine in liver transplant patients Annales de Gastroenterologie et d'Hepatologie 29(2): 81-85
Li, J.; Dahmen, U.; Beckebaum, S.; Cicinnati, V.; Valentin-Gamazo, C.; Frilling, A.; Malago, M.; Broelsch, C.E. 2006: Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients European Journal of Medical Research 11(4): 139-145